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Purpose: To present the interim ﬁndings of the Epilepsy Birth Control Registry (EBCR) regarding the
impact of various contraceptive methods on seizures, stratiﬁed by antiepileptic drug (AED) type.
Methods: This is an observational study that reports interim ﬁndings on the ﬁrst 750 subjects.
Results: There are signiﬁcantly greater relative risks (RR) for both seizure increase and decrease with
hormonal contraception (HC) than with non-hormonal contraception (NHC). The rates of HC experiences
associated with seizure increase (21.0%) are greater than with NHC (3.9%) (RR = 5.39 [95% CI = 3.77–7.73,
p < 0.0001]). The rates of HC experiences associated with seizure decrease (10.3%) are greater than with
NHC (5.6%) (RR = 1.85 [95% CI = 1.30–2.62, p = 0.0006]). While differences can reﬂect biological effects or
reporting bias, the ﬁnding of a greater RR for seizure increase with hormonal patch than with combined
oral contraceptive, perhaps related to the delivery of substantially higher concentrations of hormones,
and a greater RR for seizure decrease with depomedroxyprogesterone, known to reduce seizure
frequency when used in dosages which produce amenorrhea, support biological effects. All AED
categories showed signiﬁcantly higher frequencies of reports of seizure increase when combined with
HC than with NHC. RR for seizure increase with HC was higher with valproate than with any other AED
category. There were no signiﬁcant differences among AEDs for seizure decrease with HC at this juncture
of the study. Overall, NEIAEDs had the most favorable proﬁle with regard to reports of seizure increase
and decrease when used with HC.
Conclusions: Interim EBCR ﬁndings suggest that contraception category and interactions between
contraception category and AED category are predictive factors for changes in seizure frequency in WWE.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Family planning and contraception are important consider-
ations for women of reproductive age. They present particularly
important challenges for women with epilepsy (WWE) and their
clinicians because reproductive steroids have neuroactive proper-
ties that have the potential to impact seizures [1] and there are
reciprocal interactions between hormones and some antiepileptic
drugs (AEDs) that may impact both seizures and contraceptionAbbreviations: WWE, women with epilepsy; RR, relative risk; HC, hormonal
contraception; NHC, non-hormonal contraception; AED, antiepileptic drug; EBCR,
Epilepsy Birth Control Registry; EIAED, enzyme inducing AED; GluAED, glucuronidated
AEDs; NEIAED, non enzyme inducing AED; InhAED, enzyme inhibiting AED.
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1059-1311/ 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights re[2–4]. There is also the potential for hormonal contraception to
affect epilepsy co-morbidities such as depression and headache
which are overrepresented in WWE [5,6]. Despite the importance
of these issues, there has been little formal study of contraception
in WWE in the community and hence, a lack of evidence-based
guidelines for the selection of optimal contraceptive methods for
this special population.
2. Epilepsy Birth Control Registry
The Epilepsy Birth Control Registry (EBCR) is a collaborative
effort among medical, epidemiological/biostatistical and bioinfor-
mational technology specialists to develop a web-based survey
methodology to conduct long-term, prospective, observational
studies that will characterize the contraceptive practices of WWE
in the community, the decision making process involved in the
selection of a contraceptive method and the contraceptionserved.
Table 1a
AEDs used alone or in combination.
AED N = 1128
Lamotrigine 268 (23.8%)
Levetiracetam 217 (19.2%)
Topiramate 119 (10.5%)
Carbamazepine 75 (6.6%)
Valproate 69 (6.1%)
Zonisamide 67 (5.9%)
Oxcarbazepine 56 (5.0%)
None 45 (4.0%)
Phenytoin 39 (3.5%)
Clonazepam 33 (2.9%)
Other 33 (2.9%)
Lacosamide 30 (2.7%)
Pregabalin 24 (2.1%)
Gabapentin 16 (1.4%)
Phenobarbital 11 (1.0%)
Clobazam 10 (0.9%)
Tiagabine 8 (0.7%)
Primidone 8 (0.7%)
Table 1b
AED combinations.
AED N = 283 (>3.5%)
Lamotrigine + Levetiracetam 51 (18.0%)
Lamotrigine + Topiramate 22 (7.8%)
Levetiracetam + Topiramate 14 (4.9%)
Lamotrigine + Valproate 11 (3.9%)
Lamotrigine + Carbamazepine 10 (3.5%)
Lamotrigine + Zonisamide 10 (3.5%)
Levetiracetam + Carbamazepine 10 (3.5%)
Levetiracetam + Oxcarbazepine 10 (3.5%)
Levetiracetam + Zonisamide 10 (3.5%)
AED combinations constituting 3.5% of the 283
combinations are presented.
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tive age and age of consent between 18 and 47 years. The study aims
to generate hypotheses that will be tested in order to assess and
compare the safety and efﬁcacy of various forms of contraception
used by this special population. ‘‘Safety’’ refers to the incidence of
seizure exacerbation, as well as other speciﬁc adverse neurological,
neuropsychiatric and reproductive events that may be associated
with the use of various types of contraception. ‘‘Efﬁcacy’’ refers to the
incidence of unplanned pregnancies associated with the use of
various contraceptive methods. The ultimate goal of the project is to
develop evidence-based guidelines for safe and effective contracep-
tive practices for WWE, identify disparities in the availability and use
of optimal contraceptive methods related to demographic factors,
and develop educational interventions based on information
derived from the Registry.
The speciﬁc aims of the EBCR project are the following:
1. To characterize the contraceptive practices of WWE.
2. To characterize the decision making process.
3. To determine the impact of various contraceptive methods on
seizures, stratiﬁed by AED type.
4. To determine reasons for discontinuation of various contracep-
tive methods.
5. To estimate rates of fertility, unintended pregnancy, and
pregnancy outcomes.
6. To determine rates of folic acid use and factors that determine its
use.
This report presents the interim results of the 3rd speciﬁc aim,
i.e., the impact of various contraceptive methods on seizures,
stratiﬁed by AED type.
3. Demographic characteristics of the EBCR population
The ﬁrst 750 WWE who completed the EBCR survey, 18–47
years of age, provided the data for this interim analysis. Ninety ﬁve
percent of surveys were completed by participants located in the
USA. The average age  standard deviation of the subjects was
28.3  6.9 years; 53.3% in the 18–27 year old cohort, 35.9% in the
28–37 year old cohort and 10.8% in the 38–47 year old cohort. Using
2010 USA census ﬁgures [7], racial minorities, including Hispanic
ethnicity, were underrepresented, i.e., 8.8% of the EBCR population
versus 25.2% of the general population. Subjects had higher education
levels as compared to the general population; 83.4% had taken college
courses or had college degrees versus 59.2% in the general population.
Average household income was less than that of the general population,
i.e., 40.1% had less than 25,000 USD income as compared to 20.5% in the
general population. In summary, on average, the subjects were younger
and better educated but with lower household income than the general
population. One can speculate that younger women may be more
inclined to utilize web based information and inquire about
contraception and that younger age and the morbidity of epilepsy
may be factors in the lower income. Minorities were underrepresented
despite the great majority of participants, i.e., 77.6%, reporting that they
learned about the Project on line through Facebook, epilepsy.com and
the Epilepsy Foundation that have wide outreach.
4. Epilepsy and antiepileptic drug characteristics
Four hundred thirty four (57.9%) of the 750 WWE reported
currently having generalized convulsive seizures, 304 (40.5%),
complex partial and 198 (26.4%), simple partial seizures. One
hundred sixty four (21.9%) reported complex partial seizures as
their most severe seizure type and 76 (10.1%) reported simple
partial seizures as their most severe seizure type. Seventy six
(10.1%) of the WWE were free of seizures.The numbers and frequencies of AEDs used alone or in
combination are listed in Table 1a. 56.3% were using polytherapy,
36.6%, monotherapy and 6.0% were on no AED. The most frequent
combinations, i.e., those comprising 3.5% of all combinations, are
listed in Table 1b. To provide a meaningful power for statistical
comparisons at this stage of enrolment in the Project, AEDs were
grouped into six categories based on their effects on enzymatic
metabolism: (1) No AED, (2) enzyme inducing AEDS (EIAEDs)
which included phenobarbital, phenytoin, carbamazepine, oxcar-
bazepine and topiramate in dosages above 200 mg daily, (3)
glucuronidated AEDs (GluAEDs) which included only lamotrigine,
(4) non-enzyme inducing AEDs (NEIAEDs) which included
levetiracetam, zonisamide, gabapentin, topiramate in dosages up
to 200 mg daily, lacosamide, clobazam, pregabalin and tiagabine,
(5) enzyme inhibiting AEDs (InhAEDs) which included only
valproate, and (6) mixed categories. Note, valproate was listed
in the enzyme inhibiting category although it is also partially
glucuronidated. When there was a combination of a category that
affected enzymes and a NEIAED, the combination was listed by the
AED category that affected enzymes. If the combination was
comprised of two or more AEDs with different enzyme categories,
they were listed under the mixed category. The frequencies of use
of the AED categories are presented in Table 1c.
5. Contraceptive practices of women with epilepsy in the
community
The categories and subcategories of contraception that were in
use by the EBCR population are as follows: (1) none, (2)
withdrawal, (3) barrier (condom, diaphragm), (4) systemic
Table 1c
AEDs by categories.
AED N = 750
None 45 (6.0%)
EIAED 198 (26.4%)
GluAED 221 (29.5%)
NEIAED 207 (27.6%)
InhAED 44 (6.9%)
Mixed 35 (4.7%)
EIAED, enzyme inducing AEDs; GluAED,
glucuronidated AEDs (lamotrigine only);
NEIAED, non enzyme inducing AEDs; InhAED,
enzyme inhibiting AEDs (valproate only);
Mixed, mixed categories.
Fig. 1. Relative risks for seizure increase on various categories of contraception in
comparison to barrier category which had the lowest rate at 3.2%. Hormonal
contraception was the only category that showed a signiﬁcantly greater risk
(****p < 0.0001). Hormonal category also had a signiﬁcantly greater risk for seizure
increase than tubal (p < 0.05), IUD (p < 0.0001) and withdrawal (p < 0.0001).
Table 2b
Comparisons of subcategories of hormonal contraception on reports of seizure
change.
N Sz increase (%) Sz decrease (%)
Combined
Oral
Combined OCP 435 80 (18.4%) 40 (9.2%)
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vaginal ring; progestin only – progestin pills, implanted progestin,
depomedroxyprogesterone), (5) intrauterine device (IUD – pro-
gestin coated, copper), (6) tubal ligation, and (7) partner with
vasectomy. The 750 women reported 1581 contraceptive experi-
ences: 237 (15.0%) withdrawal, 474 (30.0%) barrier, 706 (44.6%)
systemic hormonal, 134 (8.5%) IUD and 30 (1.9%) tubal ligation.
When used in combination, the category is listed under the
generally more effective method.
6. Differential effects of the various contraceptive categories
and methods on seizure frequency
For each of the 1581 contraceptive experiences, the women
were asked the question ‘‘Do you think that this method of birth
control changed how often you had seizures?’’ Response choices
were ‘‘no change,’’ ‘‘increase,’’ or ‘‘decrease.’’ Although the majority
of responses were ‘‘no change’’ a substantial number of experi-
ences were reported to have been associated with a change in
seizures, whether increase or decrease. The numbers and
frequencies are tabulated by contraceptive category in Table 2a.
The lowest rate of seizure increase was reported with barrier
methods (3.2%) whereas the highest occurred with systemic
hormonal methods (21.0%). The relative risks of seizure increase
with each category of contraception relative to barrier, the one
with the lowest rate, are presented in Fig. 1. The relative risk of
seizure increase was signiﬁcantly and substantially greater with
hormonal contraception (HC) than with each of the categories of
non-hormonal contraception (NHC). Overall, in comparison to
non-hormonal methods, hormonal contraception had a signiﬁ-
cantly greater relative risk of both seizure increase HC: 148/706
experiences (21.0%) vs. NHC: 34/875 (3.9%); RR = 5.39 [95%
CI = 3.77–7.73, p < 0.0001] and seizure decrease HC: 73/706
(10.3%) vs. NHC: 49/875 (5.6%); RR = 1.85 [95% CI = 1.30–2.62,
p = 0.0006], with seizure increase being substantially higher
(RR = 5.39 vs. 1.85). Signiﬁcant differences between hormonal
and non-hormonal categories may reﬂect a biological effect,
reporting bias or both. In support of biological factors are some
signiﬁcant differences among the methods listed in the hormonal
category. Speciﬁcally, hormonal patch, which is the only combined
contraception method that is known to produce substantiallyTable 2a
Frequencies of seizure changes with various categories of contraception.
N = 1581 Sz increase (%) Sz decrease (%)
Withdrawal 237 11 (4.6%) 6 (2.5%)
Barrier 474 15 (3.2%) 19 (4.0%)
Hormonal 706 148 (21.0%) 73 (10.3%)
IUD 134 5 (3.7%) 19 (14.2%)
Tubal ligation 30 1 (3.3%) 5 (16.7%)higher, i.e., by 60%, serum estrogen levels than the 35 microgram
containing ethinyl estradiol pill [8,9], was associated with a
signiﬁcantly greater relative risk for seizure increase than the oral
contraceptive method (RR = 1.81, 95% CI = 1.13–2.90), the most
frequently used and lowest seizure risk hormonal contraceptive
method in the EBCR population (Table 2b). In contrast, depome-
droxyprogesterone which is known to reduce seizure frequency
when used in dosages which produce amenorrhea [10], was
associated with a signiﬁcantly greater relative risk for seizure
decrease than the oral contraceptive method (RR = 1.81, 95%
CI = 1.10–2.98; Table 2b). Both of these signiﬁcant differences in
the EBCR population are consistent with plausible biological
mechanisms of action. For example, the association of higher rates
of reports of seizure increase with hormonal patch may reﬂect the
delivery of higher concentrations of estrogen since estrogen may
have a proconvulsant effect [1]. The higher rates of reports of
seizure decrease with depomedroxyprogesterone may reﬂect the
suppression of estrogen production by the ovary in the setting of
amenorrhea. This does not exclude other plausible operant
mechanisms. We previously reviewed some of the neuroactive
properties of progesterone and estradiol [1]. Of note, however,
there is very little basic science and experimental animal evidence
regarding the neuroactive properties of the most commonNon-oral
Vaginal ring 63 16 (25.4%) 5 (7.9%)
Hormone patch 42 14 (33.3%) 3 (7.1%)
Progestin only
Oral
Progestin OCP 30 8 (26.7%) 4 (13.3%)
Non-oral
Progestin implant 16 5 (31.3%) 1 (6.3%)
DMPA 120 25 (20.8%) 20 (16.7%)
IUD, intrauterine device, Sz, seizure frequency; OCP, oral contraceptive pills; DMPA,
depomedroxyprogesterone.
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Fig. 3. Relative risk for seizure increase is presented relative to No AED rate of 20.7%.
The relative risk is greater for the enzyme inhibitory category (valproate) than for
each of the other AED categories: *p  0.05 in comparison to No AED, ##p  0.01 in
comparison to EIAED and NEIAED, !p  0.10 in comparison to GluAED.
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ethinyl estradiol, norethindrone, norgestrel and drospirenone as
they may pertain to brain substrates with epileptic discharges and
seizures. One study that examined the effects of certain estrogens
and progestins on electroshock seizure thresholds in female rats
found that, although synthetic progestins did not have a signiﬁcant
effect, co-administration with ethinyl estradiol or mestranol,
another synthetic estrogen, signiﬁcantly lowered the seizure
threshold [11]. An abstract of another study reports an increase
in seizure severity with ethinyl estradiol treatment in the baboon
[12]. Nevertheless, the evidence regarding the neuroactive
properties of contraceptive hormones is strikingly scant, given
the widespread clinical use of hormonal contraception.
7. Differential effects of antiepileptic drug categories on
changes in seizure frequency with hormonal contraception
The 750 subjects used a total of 1128 AEDs alone or in
combination. The frequencies of use alone, in combination and by
categories are presented in Tables 1a–1c. The frequencies of
reports of seizure increase on HC and NHC, stratiﬁed by AED
monotherapy category is presented in Fig. 2. All of the AED
categories showed signiﬁcantly and substantially higher frequen-
cies of reports of seizure increase when combined with HC as
compared to NHC.
Binary logistic regression showed an interaction between
contraception category and AED category as a predictive factor
for seizure increase (p < 0.001). Odds ratios were signiﬁcant for
interactions between AED categories and hormonal but not non-
hormonal categories of contraception. In comparison to the Barrier
and No AED combination, odds ratios were as follows: Hormonal
and InhAED (valproate), OR = 6.220 (3.025–12.791), p = 0.0005;
Hormonal and GluAED (lamotrigine), OR = 2.773 (1.535–5.009),
p = 0.001; Hormonal and EIAEDs, OR = 2.258 (1.257–4.057),
p = 0.006; Hormonal and NEIAED, OR = 2.014 (1.026–3.955),
p = 0.042. The relative risks for seizure increase on HC, stratiﬁed
by AED monotherapy category is presented in Fig. 3. The enzyme
inhibiting category, valproate, showed a trend for or signiﬁcantly
greater risk for seizure increase as compared to each of the other
AED categories. Of note, in 40 experiences on valproate + HC use,
seizure increase was reported in 15 (37.5%) whereas there were no
reports (0.0%) of seizure increase in 43 experiences on valproa-
te + NHC (Fisher’s exact test for seizure increase: p < 0.0001). In
contrast, seizure decrease reports with valproate were very similar
for the HC and NHC groups: 2/40 (5.6%) on valproate + HC versusFig. 2. Seizure frequencies are greater on hormonal contraception (HC) than on non-
hormonal (NHC) contraception for each AED monotherapy category: *p  0.05,
**p  0.01, ***p  0.001, ****p  0.0001.2/43 (4.7%) on valproate + NHC (Fisher’s exact test for seizure
decrease: p = NS) (Table 3).
Binary logistic regression also showed an interaction between
contraception category and AED category as a predictive factor for
seizure decrease (p = 0.006). Odds ratios again were signiﬁcant for
interactions between AED categories and hormonal but not non-
hormonal categories of contraception. Odds ratios for interaction
between hormonal contraception and AED category relative to the
Barrier and No AED category were as follows: Hormonal and
NEIAED, OR = 3.896 (1.762–8.618), p = 0.001; Hormonal and
EIAED, OR = 2.950 (1.384–6.286), p = 0.005; Hormonal and GluAED
(lamotrigine), OR = 2.271 (0.994–5.191), p = 0.052; Hormonal and
InhAED (valproate), OR = 1.039 (0.225–4.790), p = 0.961. A com-
parison of the relative risks for seizure decrease on hormonal
contraception for each of the 4 categories of AED monotherapy
versus no AED category showed no signiﬁcant difference at this
juncture in the study. Relative to No AED which was associated
with reports of seizure decrease in 8.5% of the HC experiences, the
RR for EIAED was 0.7360 (95%CI: 0.4229–1.2808), for GluAED
(lamotrigine) was 0.6794 (0.3638–1.2688), for NEIAED was 1.1846
(0.4622–3.0358) and for InhAED (valproate) was 0.5857 (0.1274–
2.6924). Of note, the RR for seizure decrease was two times greater
on NEIAEDs (1.1846) which had the highest RR as compared to
valproate (0.5857) which had the lowest RR.
8. Hormonal contraception, AEDs and seizures in women with
epilepsy
As part of family planning, it is important for women with
epilepsy to know what constitutes safe and effective contracep-
tion. A relatively recent authoritative review [13] states that ‘‘there
is no evidence that oral contraceptives increase seizure activity.’’
This view is generally consistent with prior authoritative reviewsTable 3
Frequencies of changes in seizure frequency on valproate monotherapy stratiﬁed by
contraception type.
N Sz increase (%) Sz decrease (%)
Valproate
Hormonal contraception 40 15 (37.5%) 2 (5.6%)
Non-hormonal contraception 43 0 (0.0%) 2 (4.7%)
Sz, seizure frequency.
Fisher’s exact test for seizure increase: p < 0.0001.
Fisher’s exact test for seizure decrease: p = NS.
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are lacking.
The EBCR Project utilizes a web-based survey to access a large
representative sample of women with epilepsy in the community.
The large sample size is required to control for the many
demographic, epilepsy, AED and contraceptive variables in the
analysis. The EBCR preliminary ﬁndings are, by patient reports,
that HC is associated with a broader dynamic range of seizure
responses manifested by a signiﬁcantly greater risk for both
seizure increase and decrease than NHC but with the relative risk
for seizure increase predominating. Seizure increase is signiﬁcant-
ly more likely to occur with all AED categories in combination with
HC than with NHC. The odds ratio for seizure increase with HC
appears to be greater for the enzyme inhibiting category,
speciﬁcally valproate, than for any other AED category in relation
to the reference combination of Barrier and No AED. With HC,
valproate showed a greater relative risk for seizure increase as
compared to any other AED category. The occurrence of a greater
increase in seizures with valproate as compared to other AEDs is
now raised as a potential issue but remains to be veriﬁed in the full
study. A pathophysiological mechanism remains to be demon-
strated. HC lowers glucuronidated AED serum levels. This has been
demonstrated for valproate as well as lamotrigine. The lowering of
AED levels, however, would not be an entirely adequate explana-
tion since lamotrigine levels are found to drop more than valproate
with HC [15], yet the rates of reports of seizure increase with HC
are greater when combined with valproate (37.5%) than with
lamotrigine which had a rate very similar to No AED (23.3% vs.
20.0%) in the EBCR population. Another consideration is that these
AEDs may have differential effects on contraceptive hormone
levels. Whereas lamotrigine has an insigniﬁcant lowering effect on
ethinyl estradiol levels [16], might the enzyme inhibiting valproate
possibly raise ethinyl estradiol levels in women? Higher serum
estradiol levels on valproate treatment have been reported to occur
in men with epilepsy as compared to healthy controls (0.25  0.10
on a mean daily dose of 986  285 mg vs. 0.15  0.08 nmol/L;
p < 0.01) [17]. There is as yet no conclusive evidence in this regard for
ethinyl estradiol in women with epilepsy. One study of ethinyl
estradiol levels before and after introduction of valproate therapy
reported no signiﬁcant difference [18]. The study of only six women,
however, lacked power to detect a moderate valproate effect and did
ﬁnd an 11% higher, albeit statistically insigniﬁcant, increase in the
area under the curve for ethinyl estradiol as compared to a 0.3%
increase for levonorgestrel, even on a clinically low dose of valproate
200 mg bid. Of course, the impact of valproate may relate to changes
in the concentrations of other neuroactive steroids not under
consideration here. Among the AED categories, NEIAEDs had the
most favorable proﬁle with regard to reports of seizure increase and
decrease when used in combination with HC.
The EBCR is currently still gathering retrospective data and is
addressing the limitations of the retrospective survey by conduct-
ing a pilot to determine whether the methodology may be effective
in retaining a representative population for the conduct of a long-
term, prospective, serial survey study. A validation study is also
required. Given the importance of family planning and the largevolume of hormonal contraception use by women with epilepsy,
further basic science studies are also important to establish the
neuroactive properties of contraceptive hormones as they pertain
to seizures and the effects of valproate on ethinyl estradiol levels.
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